Zevra Therapeutics, Inc. — Key Metrics
2 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
M-Score (Beneish; >-1.78 flags risk)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
EPS (Diluted)
$1
Book Value Per Share
$3
Free Cash Flow Per Share
$-0
Cash Per Share
$1
Revenue Per Share
$2
OCF Per Share
$-0
Return on Equity
85.7%
Return on Assets
36.0%
Return on Invested Capital
-38.3%
Debt to Equity
0.40
Current Ratio
5.68
Quick Ratio
5.63
Asset Turnover
0.46
Days Sales Outstanding
157.30
Days Payables Outstanding
54.88
Days Inventory On Hand
38.53
Cash Conversion Cycle
-389.19
R&D / Revenue
12.0%
SBC / Revenue
11.9%
Capex / Revenue
0.8%
Working Capital
$184M
Net Current Asset Value
$93M
Invested Capital
$217M
OCF / Net Income
-0.02
FCF / Net Income
-0.03
Accruals Ratio (Sloan)
29.8%
Net Debt
$-478K
Net Debt / EBITDA
0.01
Interest Coverage
-7.89
Cash Coverage
-0.20
Capex Coverage
-1.91
Tangible Common Equity
$144M
TCE / Total Assets
50.4%
Goodwill / Total Assets
1.7%
NOPAT
$-60M
Cash ROIC
-1.5%
WC / Revenue
172.6%
Capex / D&A
0.21
Reinvestment Rate
5.1%
Total Payout Ratio
0.0%
Asset Growth vs Revenue Growth
-291.1%
Revenue 5Y CAGR
51.6%
Stock Price (FY-end)
$9
Market Cap
$513M
P/E Ratio
6.16
P/S Ratio
4.82
P/B Ratio
3.32
P/TB Ratio
3.57
P/OCF Ratio
—
P/FCF Ratio
—
Enterprise Value
$513M
EV / EBITDA
—
EV / Sales
4.81
EV / FCF
—
FCF Yield
-0.5%
Shareholder Yield
-2.5%
Buyback Yield
0.0%
R&D Yield
2.5%
Capex Yield
0.2%
Graham Number
$9
Shares Variation (YoY)
23.8%
Beta (5Y)
0.88
Cost of Equity
8.9%
Cost of Debt (after tax)
12.4%
WACC
9.3%
ROIC - WACC Spread
-47.6%
52W High
$13
52W Low
$7
Trailing Return 1Y
6.8%
Trailing Return 5Y
-43.8%
F-Score (Piotroski)
6.00
M-Score (Beneish)
-7.21
Z-Score (Altman)
0.71
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.